MAP3K8 and pulmonary fibrosis: It was recently reported that TPL-2–deficient mice, or inhibition of ERK [31], protected mice from type-1/TH17 and TGFβ-mediated pulmonary fibrosis following bleomycin treatment [31] and from hepatic fibrosis following carbon tetrachloride and methionine choline-deficient diet-induced fibrosis [32].